Trinity Capital Inc. announced on March 10 2026 that it is providing a $35 million growth‑capital facility to Neuros Medical, Inc., a MedTech company whose FDA‑approved Altius Direct Electrical Nerve Stimulation System treats chronic post‑amputation pain. The new debt facility follows a $25 million investment made by Trinity in October 2023 and is intended to accelerate commercialization and expand the company’s reach into new markets.
Neuros Medical’s Altius system received FDA approval on August 28 2024 and offers a non‑opioid, patient‑controlled alternative for post‑amputation pain. The additional capital will support the scaling of the Altius platform, including manufacturing, regulatory compliance, and market entry initiatives, with a focus on expanding the product’s availability beyond the United States.
Trinity Capital’s Q4 2025 results underscored the strategic fit of this investment. The BDC reported total investment income of $83.2 million and net investment income of $39.9 million, while its net asset value grew year‑over‑year. With a debt‑to‑equity ratio of 1.18, the new facility adds to a portfolio that has been expanding its life‑sciences exposure and reinforces Trinity’s strategy of providing tailored debt solutions to growth‑oriented, venture‑backed companies.
Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, said, "Neuros Medical has reached an important inflection point as their technology moves into real‑world adoption. We are proud to continue to support their team as they expand access to a differentiated therapy that addresses a significant need within the life sciences ecosystem." David Veino, President & CEO of Neuros Medical, added, "We appreciate the continued partnership from Trinity. The Trinity team has been an important partner prior to us achieving FDA approval and will remain an important partner as we expand. This expansion of our debt facility provides important financial flexibility as Neuros enters the next phase of its mission to Relieve Pain and Restore Life for this underserved patient population."
Trinity Capital’s stock rose 1.41% in pre‑market trading to $15.07 following the announcement, reflecting investor confidence in the company’s continued focus on life‑sciences financing and the growth potential of the Altius system.
The $35 million commitment signals strong confidence in Neuros Medical’s technology and expansion plans, while reinforcing Trinity Capital’s position as a key financing partner for innovative medical‑technology companies. The deal provides Neuros with the financial flexibility needed to scale production, navigate regulatory requirements, and pursue new market opportunities, positioning both companies for continued growth in the evolving pain‑management landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.